+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of the drug NNC0487-0111 in adults with excess body weight and moderate-to-severe obstructive sleep apnoea OSA who are not treated with positive airway pressure. This Phase 3 study randomizes participants to receive either NNC0487-0111 or a placebo to assess their ability to lose weight and improve sleep apnoea symptoms. Participants will receive weekly injections under the skin using pre-filled pen-injectors of either NNC0487-0111 or placebo. Both groups will follow a reduced-calorie diet and increase physical activity. The treatment period lasts 80 weeks, during which the effects on body weight and sleep apnoea will be monitored. During the study, participants will have regular assessments including measurements of body weight, apnoea-hypopnoea index AHI, sleepiness scales, blood pressure, cholesterol levels, blood sugar, and other health indicators. Safety will be monitored through tracking adverse events up to 84 weeks. The study aims to measure changes from baseline to week 80 to evaluate treatment impact.

Age: 18Years +All GendersPhase 3
80 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of a medicine called NNC0487-0111 in adults with overweight or obesity who also have moderate-to-severe obstructive sleep apnoea OSA treated with positive airway pressure. This Phase 3 study compares NNC0487-0111 to a placebo to see how well it helps reduce body weight and improve sleep apnoea symptoms over time. Participants will be randomly assigned to receive one of these treatments, which are injected under the skin weekly. Participants will receive either one of two dose levels of NNC0487-0111 or a matching placebo injection once a week. Both groups will also follow a reduced-calorie diet and increase physical activity as part of the study. The injections are given using pre-filled pen-injectors at areas such as the thigh, abdomen, or upper arm. The treatment period lasts up to 80 weeks, during which body weight and sleep apnoea severity are closely monitored. Throughout the study, participants will have regular assessments to measure changes in body weight, apnoea-hypopnoea index AHI, sleep quality, blood pressure, blood sugar, cholesterol, and other health markers. Safety is monitored by tracking adverse events until week 84. The study also evaluates improvements in sleep-related symptoms and the potential to reduce or stop positive airway pressure therapy. Total participation may last up to 84 weeks, including follow-up for safety and health outcomes.

Age: 18Years +All GendersPhase 3
92 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNC0487-0111 in adults with excess body weight and knee osteoarthritis. This phase 3 study compares NNC0487-0111 to a placebo to determine its impact on weight loss and knee pain reduction. Participants have symptomatic knee osteoarthritis confirmed by clinical and radiographic criteria and experience knee pain for more than 90 days. Participants receive subcutaneous injections of either NNC0487-0111 or placebo once weekly. Both groups follow a reduced-calorie diet and increased physical activity as part of the treatment plan. The study uses pre-filled pen-injectors for administration at one of three body sites thigh, abdomen, or upper arm. The treatment period lasts up to 80 weeks. During the study, participants will be monitored through various assessments including body weight, knee pain using the WOMAC pain score, physical function, blood pressure, cholesterol levels, blood glucose, and use of pain medications. Safety will be tracked by recording adverse events up to 84 weeks. Participants will complete questionnaires and have clinical evaluations at regular intervals throughout the trial.

Age: 18Years +All GendersPhase 3
81 locations
C

Actively Recruiting

Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.

Age: 45Years +All GendersPhase 3
330 locations